https://magazine.pharmamkt.net/2019/05/06/springworks-therapeutics-announces-initiation-of-phase-1b-clinical-trial-of-mek-inhibitor-pd-0325901-in-combination-with-beigenes-raf-dimer-inhibitor-lifirafenib-in-advanced-or-refractory-sol/